Table 1.
Parameter (if appropriate performed) | Visit 1 (baseline start) | Subsequent visits (intervals corresponding to routine clinical practice) |
---|---|---|
Informed consent | X | |
Patient code | X | X |
Date of visit | X | X |
Patient data (gender, date of birth) | X | |
Primary diagnosis (date, evidenced indication, indication-specific characteristics) | X | |
Family history | X | |
Pregnancy | X | |
Birth history | X | |
Previous auxological data | X | |
Physical examination | X | |
Relevant medical history and concomitant diseases | X | |
Concomitant medication/therapies | X | X |
Previous clinical trial participation | X | |
Previous GH treatment | X | |
Omnitrope® treatment | X | X |
Current auxological data | X | X |
Vital signs | X | X |
Pubertal development | X | X |
Bone age | X | X |
Body composition | X | X |
Haematology | X | X |
Blood chemistry | X | X |
Glucose metabolism/OGTT | X | X |
Fasting lipid profile | X | X |
Urinalysis | X | X |
Hormones (thyroid, gonadal, adrenal function) | X | X |
IGF-I, IGFBP-3 determinations | X | X |
Anti-HGH antibody determination | X | X |
Adverse events | X | |
Pregnancy reporting | X | |
Medical device vigilance reports | X | |
Discontinuation (reasons) | X |
IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; OGTT, oral glucose tolerance test.